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Wilms tumor is the most common pediatric kidney
cancer. To identify transcriptional and epigenetic
mechanisms that drive this disease, we compared
genome-wide chromatin profiles of Wilms tumors,
embryonic stem cells (ESCs), and normal kidney.
Wilms tumors prominently exhibit large active chro-
matin domains previously observed in ESCs. In the
cancer, these domains frequently correspond to
genes that are critical for kidney development and
expressed in the renal stem cell compartment. Wilms
cells also express ‘‘embryonic’’ chromatin regulators
and maintain stem cell-like p16 silencing. Finally,
Wilms and ESCs both exhibit ‘‘bivalent’’ chromatin
modifications at silent promoters that may be poised
for activation. In Wilms tumor, bivalent promoters
correlate to genes expressed in specific kidney com-
partments and point to a kidney-specific differentia-
tion program arrested at an early-progenitor stage.
We suggest that Wilms cells share a transcriptional
and epigenetic landscape with a normal renal stem
cell, which is inherently susceptible to transformation
and may represent a cell of origin for this disease.
INTRODUCTION
The fundamental role of genetic changes in cancer progression
is now unquestioned. These aberrations are being cataloged at
an unprecedented pace through the application of high-
throughput genomic tools (Stratton et al., 2009). In contrast,
the extent to which epigenetic events and chromatin environ-
ments contribute to cellular transformation remains controver-
sial. The genomic instability present in many cancers compli-cates the study of DNA methylation and chromatin. Moreover,
the most relevant self-renewing cell populations are frequently
obscured by tumor heterogeneity. Nonetheless, there is in-
creasing evidence that aberrant DNA methylation and chromatin
regulation profoundly contribute to specific types of cancer
(Feinberg et al., 2006; Jones and Baylin, 2007). The advent of
new epigenomic tools provides an opportunity to investigate
their contributions broadly (Barski et al., 2007; Lister et al.,
2009; Mikkelsen et al., 2007). Pediatric cancers represent attrac-
tive models to study because their relatively normal genomic
background facilitates epigenomic characterization and sug-
gests that epigenetic factors may play particularly critical roles
in pathogenesis.
Wilms tumor is characterized by a multipotent ‘‘triphasic’’
histology that includes an undifferentiated ‘‘blastemal’’ compo-
nent and varying amounts of epithelial and stromal elements
(Rivera and Haber, 2005). These tumors can also be associated
with developmental abnormalities, including persistent embry-
onic tissue known as nephrogenic rests, and are thus believed
to be intimately connected to kidney organogenesis.
Genetic abnormalities described in Wilms tumor involve genes
that regulate the metanephric mesenchyme, a kidney-specific
stem cell population that resembles blastemal tumor cells and
gives rise to most epithelia in adult kidneys. The tumor sup-
pressor WT1 has been linked to survival and differentiation of
these cells (Call et al., 1990; Gessler et al., 1990; Kreidberg
et al., 1993; Moore et al., 1999), and the activation of b-catenin
is a crucial step in epithelialization (Koesters et al., 1999). Simi-
larly, the recently identified tumor suppressor WTX is expressed
in kidney stem cells and has been linked to Wnt signaling and
WT1 transcriptional control (Major et al., 2007; Rivera et al.,
2007; Rivera et al., 2009). Yet known mutations account for
less than 50% of Wilms tumors, leaving a majority without any
known causal genetic alteration.
Two aspects of Wilms tumor suggest that epigenetic alter-
ations also play critical roles in pathogenesis. First, the classicalCell Stem Cell 6, 591–602, June 4, 2010 ª2010 Elsevier Inc. 591
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allele, frequently exhibits biallelic expression in sporadic Wilms
tumors (Ogawa et al., 1993). IGF2 imprinting is also lost in
Beckwith-Wiedeman, an overgrowth syndrome associated
with an elevated risk of Wilms tumors (Weksberg et al., 1993).
Second, similarities in gene expression between Wilms tumor
and fetal kidney raise the possibility that pathways active in
organ-specific stem cells may be shared by the tumor (Li et al.,
2002). This relationship is further supported by the occasional
spontaneous regression of nephrogenic rests, which may reflect
the reactivation of kidney differentiation pathways (Beckwith
et al., 1990).
Whole-genome analysis of chromatin state is now feasible
by combining chromatin immunoprecipitation (ChIP) with se-
quencing (ChIP-Seq) (Barski et al., 2007; Mikkelsen et al.,
2007). Of particular interest are specific histone modifications
that relate closely to transcriptional programs, cellular state,
and epigenetic processes (Kouzarides, 2007). Maps of histone
H3 trimethylated at lysine 4 (K4me3), lysine 36 (K36me3), or
lysine 27 (K27me3) identify promoters, transcripts, or sites of
Polycomb repression, respectively (Barski et al., 2007; Li et al.,
2007; Mikkelsen et al., 2007). In embryonic stem cells (ESCs),
‘‘bivalent domains’’ with overlapping K27me3 and K4me3 are
associated with developmental genes that are presently silent,
but poised for activation upon differentiation (Azuara et al.,
2006; Bernstein et al., 2006). Bivalent domains have been
proposed to predispose gene promoters to DNA methylation in
cancer (Ohm et al., 2007). However, the global role of such marks
in cancer has not been explored. Such an analysis could provide
insight into the developmental state of tumor cells and how they
relate to nonmalignant counterparts.
Here, we present a whole-genome analysis of chromatin in
primary Wilms tumors. We focused on Wilms as an initial model
because (1) resected tumors provide a ready source of homoge-
neous, undifferentiated ‘‘blastemal’’ cells that resemble embry-
onic renal tissue and may represent a model of tumor stem cells
(Rivera and Haber, 2005) and (2) Wilms cells exhibit relatively
normal genetic backgrounds with few copy number alterations
or known mutations, thus facilitating and highlighting the impor-
tance of epigenomic analysis (Rivera et al., 2007). We mapped
K4me3, K27me3, and K36me3 in Wilms tumors, normal kidneys,
and fetal kidneys, and we compared the maps to analogous data
for human ESCs. These chromatin data were integrated with
published transcript profiles and complemented by mutation
and copy number analyses.
The data reveal an interconnected network of genes that
appear to drive Wilms tumor phenotype and proliferation.
Many of these genes correspond to known regulators of kidney
development, but some may be novel master regulators of this
process. The maps also point to critical roles for Polycomb
repression in both fully silenced and bivalent patterns, an impor-
tant feature of ESC biology that is recapitulated in Wilms tumor.
For example, the p16 tumor suppressor is repressed by Poly-
comb in a manner reminiscent of normal stem cells, but distinct
from many adult tumors. Similarly, markers of epithelial differen-
tiation are maintained in a bivalent, poised state that may signal
a latent differentiation potential akin to a normal renal stem cell.
In summary, in-depth analysis of Wilms tumor chromatin points
to a transformed phenotype that is sustained through the precise592 Cell Stem Cell 6, 591–602, June 4, 2010 ª2010 Elsevier Inc.control of developmental and proliferative mechanisms shared
with early kidney precursors and ESCs.
RESULTS
Genome-wide Maps of Chromatin State in Wilms Tumor
Genome-wide chromatin maps were generated for three WTX
mutant Wilms tumors, normal kidney, and fetal kidney via
ChIP-Seq. We selected tumors with pronounced blastemal
compartments and few large-scale copy number changes in
order to enrich for homogeneous tumor cells with defined
genetic abnormalities. These tumors did not contain alterations
in WT1 or b-catenin. After manually dissecting blastemal com-
partments, we performed ChIPs for K4me3, K27me3, or
K36me3 (see Experimental Procedures). ChIP DNA was se-
quenced on an Illumina Genome Analyzer and reads were
aligned to the human genome (hg18) to produce density maps
and identify genomic intervals enriched for a given modification
(Mikkelsen et al., 2007). These data were integrated with maps
of ESC chromatin (Ku et al., 2008), with sequence-based anno-
tations for promoters, transcripts, and other genomic features,
and with transcript profiles for Wilms tumors and other renal
tissues (Brunskill et al., 2008; Yusenko et al., 2009). Although
we focused our analysis on these WTX mutant tumors, we also
mapped K4me3 in a WT1 mutant tumor for comparison. Chro-
matin data sets are summarized in Tables S1–S5 available online
and are publicly available at http://www.broadinstitute.org/cgi-
bin/seq_platform/chipseq/shared_portal/clone/Wilms.py and at
Gene Expression Omnibus (GEO).
Shared Patterns of Active Chromatin in Wilms Tumor
and ESCs
We began our analysis by comparing promoter states across the
different samples, focusing on K4me3 as a marker of transcrip-
tional initiation (Li et al., 2007). We annotated promoters based
on the presence of K4me3 and performed unsupervised clus-
tering of the various samples. As expected, all three WTXmutant
Wilms tumors cluster closely (Figure 1A; Figure S1). Remarkably,
K4me3 patterns in the tumors resemble those in ESCs to a signif-
icantly greater extent than those in normal kidney. This relation-
ship does not extend to other precursor populations, as indicated
by the fact that Wilms tumors more closely resembled ESCs than
hematopoietic progenitors (Figure S1; Cui et al., 2009).
Wilms tumors also resembled ESCs with respect to the chro-
matin patterns seen at developmental loci. Both cell types ex-
hibit an overabundance of broad K4me3 intervals or ‘‘domains’’
that contrast markedly with the punctate K4me3 peaks seen at
typical promoters (Figures 2A and 2B).
Active Chromatin Domains Mark Kidney Development
Genes in Wilms Tumor
In ESCs, the largest K4me3 domains coincide with master regu-
lators of pluripotency, including OCT4 and SOX2 (Mikkelsen
et al., 2007). Initial examination of our data suggested a similar
effect in Wilms tumor. For instance, one of the largest K4me3
domains in Wilms tumor overlaps SIX2, which encodes a tran-
scription factor (TF) with essential functions in maintaining
kidney stem cells in an undifferentiated state (Figures 2B and
2C; Kobayashi et al., 2008; Self et al., 2006). SIX2 is expressed
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Figure 1. Gene Classification Based on Chromatin Provides Insights into the Developmental State of Wilms Tumor
(A) Wilms tumors, normal kidney, and ESCs were clustered by K4me3 promoter states. The cluster tree depicts relationships among these different tissues.
(B and C) Four gene sets were defined based on promoter chromatin states. For each set, chromatin profiles are shown for a typical gene. These profiles depict
ChIP-Seq signals for the indicated modification. The x axis corresponds to genome position. The y axis corresponds to the number of sequenced ChIP fragments
that overlap a given position (range = 0–12).
Set 1 contains genes with broad K4me3 domains in Wilms tumor; it is enriched for known regulators of kidney and mesoderm development (top two categories
shown). Set 2 contains genes with promoter K4me3 peaks in Wilms tumor and ESCs, but not in normal kidney; it is enriched for regulators of chromatin,
transcription, and epigenetic processes. Set 3 contains genes with overlapping K4me3 and K27me3 in Wilms tumor, a subset of which is differentially expressed
in kidney (see text and Figure 3). Set 4 contains genes with promoter K27me3 in Wilms tumor it is enriched for genes involved in distinct developmental processes.
See also Figure S1, Tables S1–S5.
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Wilms Tumor Chromatin Profilesat high levels in Wilms tumor relative to other renal tumors and
adult kidneys (Figure 2D; Yusenko et al., 2009). We also detected
a strong signal for SIX2 protein in the blastemal compartments of
tumor sections by immunofluorescence (Figure 2E). A similar
signal is detected in the metanephric mesenchyme, the renal
stem cell compartment in developing kidneys. Another K4me3
domain coincides with GDNF, which encodes a growth factor
that is expressed in kidney stem cells and which is an essentialregulator of kidney development (Figure 1B; Moore et al., 1996;
Sa´nchez et al., 1996).
This observation prompted us to test whether the presence of
K4me3 domains could be used to identify genes that underlie
Wilms tumor biology. We therefore examined the set of genes
that, like SIX2 and GDNF, are marked by the broadest K4me3
domains in Wilms tumor (K4me3 interval > 3.5 kb) but are
unmarked in normal kidney (K4me3 interval < 0.7 kb). ThisCell Stem Cell 6, 591–602, June 4, 2010 ª2010 Elsevier Inc. 593
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Figure 2. Domains of Modified Histones Identify Developmental Regulators in Wilms Tumor
(A) Histograms depict the size distribution of K4me3-enriched regions in ESCs, Wilms tumor, fetal kidney, and normal kidney. In both ESCs and Wilms tumor, the
most expansive regions correspond to developmental genes with critical roles in the respective cell types. 95th percentile values (5.4 kb for ESCs, 4.8 kb for Wilms
tumor, and 3.9 kb for both fetal and normal kidney) are indicated on each plot.
(B) Genomic views show K4me3 signal in Wilms tumor for a typical promoter (GAA) and for the kidney stem cell regulator SIX2.
(C and F) K4me3 signal at the SIX2 and SOX11 loci in Wilms tumor compared to normal kidney.
(D and G) Expression ofSIX2 andSOX11mRNA shown for a panel of renal tumors and tissues. Abbreviations: a, clear cell sarcoma of the kidney; b, collecting duct
carcinoma; c, chromophobe renal cell cancer; conventional renal cell carcinoma; fetal kidney; d, renal lipoma; adult kidney; papillary renal cell carcinoma; e, renal
oncocytoma; f, rhabdoid tumor of kidney; Wilms tumor.
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Figure 3. Gene Sets Defined by Chromatin State
in Wilms Tumor Show Differential Expression
Patterns in Normal and Malignant Kidney Tissues
Row-normalized heat maps depict relative expression of
genes in Set 1 and Set 3. Red indicates high levels of
expression; blue indicates low or no expression.
(A) Genes in Set 1 (broad K4me3) are preferentially ex-
pressed in Wilms tumor and fetal kidney (Yusenko et al.,
2009).
(B) Genes in Set 3 show relatively greater expression in
adult kidney, and heterogeneous expression in conven-
tional renal cell carcinoma (cRCC).
See also Figure S2.
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Wilms Tumor Chromatin Profilesproduced a list of 114 genes (Set 1; Table S2). Set 1 genes show
higher expression in Wilms tumor relative to normal kidney tissue
(Figure 3A), as expected from their active chromatin states. In
addition, genes in this set exhibit relatively strong enrichment
for K36me3, a chromatin mark that typically coats active tran-
scripts (Figure S2).(E and H) Immunofluorescence images depict SIX2 and SOX11 protein expression in a WTX mutan
SOX11 have similar expression in the blastemal compartment (dotted outlines). In fetal kidney both
mesenchymal and epithelial precursors are located (dotted lines). Original magnification 2003.
(I and J) Genomic views show noncoding RNA genes with broad K4me3 domains in Wilms tumor.
See also Tables S6 and S7.
Cell Stem Cell 6With the Gene Ontology Database, we con-
firmed that Set 1 is highly enriched for genes
with functions in kidney and mesoderm devel-
opment (Figure 1B). In addition to GDNF and
SIX2, Set 1 contains 23 other well-characterized
nephrogenesis regulators such as EYA1 and
OSR1 (Table S6; Brodbeck and Englert, 2004;
Mugford et al., 2008). Set 1 genes are highly
expressed in fetal kidney, consistent with the
enrichment for developmental functions. Impor-
tantly, Set 1 genes do not appear to be general
features of cancer, as indicated by the fact that
they are expressed at much lower levels in adult
renal cell carcinoma (Figure 3A; Yusenko et al.,
2009). Taken together, these findings suggest
that Wilms tumor cells may be driven by a tran-
scriptional regulatory network analogous to
renal progenitors.
Identification of Potentially Novel
Regulators of Wilms Tumor
and Kidney Development
Because many Set 1 genes have not been
previously linked to kidney development, we
explored whether these candidates might also
play roles in this process. In fact, many Set 1
genes without previously described kidney
functions are expressed in a pattern similar to
SIX2, with high levels in Wilms tumor and fetal
kidney and considerably reduced signals in
other renal tumors and adult kidney. One inter-
esting candidate is SOX11, which encodes aTF with defined roles in neurons and mesenchymal stem cells
(Figures 2F and 2G; Kubo et al., 2009). With immunofluores-
cence, we confirmed that SOX11, like SIX2, is expressed in the
blastemal compartment of Wilms tumor (Figure 2H). In fetal
kidney, SOX11 protein is detected adjacent to the surface of
the organ, where mesenchymal and epithelial precursors reside.t Wilms tumor and fetal kidney. In Wilms tumor, SIX2 and
markers are adjacent to the surface of the organ where
, 591–602, June 4, 2010 ª2010 Elsevier Inc. 595
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Figure 4. Chromatin Regulators in Wilms Tumor and ESCs
Genomic views depict K4me3 and K27me3 signals for (A) HDAC4, (B) CBX2, and (C) JARID2, genes encoding key chromatin regulators that are common to
Wilms tumor and ESCs, but inactive in normal kidney and adult renal cancers. The highlighted genes are examples of ‘‘embryonic’’ chromatin regulators active
in Wilms tumor.
See also Figure S3, Tables S8 and S9.
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Wilms Tumor Chromatin ProfilesThis suggests a role for this TF in renal precursors during
embryogenesis. Thus, an unbiased screen for K4me3 domains
in Wilms tumor reveals genes with previously unrecognized
functions in tumor biology and early kidney development.
Roughly 10% of the large K4me3 domains in Wilms tumor do
not correspond to annotated protein coding genes. Recently,
a variety of noncoding RNAs have been identified by genome-
wide screens, in part through their associations with K4me3
and other histone modifications (Guttman et al., 2009; Marson
et al., 2008; Mikkelsen et al., 2007). We therefore asked whether
chromatin domains that do not correspond to classical gene
annotations could reflect the regulation of noncoding RNAs in
Wilms tumor. We identified several striking examples (Table S7).
One prominent K4me3 domain corresponds to a cluster of three
microRNAs on chromosome 19: mir-99b, let-7e, and mir-125a
(Figure 2I). Though they remain poorly characterized, these
miRNAs have been implicated in several malignancies (Li
et al., 2009; Wu et al., 2008, 2009). HOTAIR, a large noncoding
RNA in the HOXC cluster with known associations to cancer
(Rinn et al., 2007), is also marked by a large K4me3 domain in
Wilms tumor (Figure 2J). Interestingly, HOTAIR also shows
variable degrees of K27me3 in the tumors. These signature
chromatin patterns suggest possible roles for these and other
noncanonical elements in Wilms tumor biology and/or kidney
development.
An ‘‘Embryonic’’ Repertoire of Chromatin Regulators
in Wilms Tumor
To further explore commonalities between Wilms and ESCs, we
examined genes whose promoters have compact K4me3 peaks
in both cell types, but which lack this mark in normal kidney
(Figure 1B). This produced a list of 793 genes (Set 2; Table S3).
Set 2 is statistically enriched for genes with annotated functions
in chromatin, epigenetic, and transcriptional regulation (Fig-
ure 1B). It includes numerous chromatin regulators that are596 Cell Stem Cell 6, 591–602, June 4, 2010 ª2010 Elsevier Inc.highly expressed in embryonic tissues and stem cells and which
could contribute to a stem cell-like chromatin state in the tumor.
We compiled a list of 60 chromatin regulators in Set 2 (Figure 4A;
Table S8). As expected, these genes tend to be expressed at
high levels in Wilms and ESCs. They also show high expression
in fetal kidney, but are relatively silent in adult kidney. The regu-
lators do not appear to be simply markers of proliferation
because they are expressed at much lower levels in renal cell
carcinoma (Figure S3; Yusenko et al., 2009).
Many of these 60 chromatin regulators have documented
roles in embryogenesis, kidney development, and self-renewal.
JARID2, FBXL10, andCBX2 are all linked to Polycomb silencing.
JARID2 and FBXL10 encode members of the jumonji protein
family, several of which have histone demethylase activity (Kou-
zarides, 2007). JARID2 is a component of PRC2, the Polycomb
repressive complex that catalyzes K27me3 (Li et al., 2010;
Peng et al., 2009; Shen et al., 2009). FBXL10 and CBX2 encode
subunits of Polycomb repressive complex 1 (Sa´nchez et al.,
2007). Polycomb repressors play particularly important and
dynamic roles in the maintenance of lineage-specific gene
expression programs during early development (Sparmann and
van Lohuizen, 2006). In addition, FBXL10 and PR-Set7, another
Set 2 member, have been implicated in proliferation and antise-
nescence through the regulation of p15- and p53-dependent
pathways (He et al., 2008; Shi et al., 2007).
NSD1 and WHSC1, which encode K36 methyltransferases,
have been previously linked to Wilms tumor and developmental
kidney disorders (Bergemann et al., 2005; Kurotaki et al., 2002;
Nimura et al., 2009; Wang et al., 2007). NSD1 is inactivated
in Sotos syndrome, a congenital condition associated with
increased susceptibility to Wilms tumors, and WHSC1 is named
for Wolf-Hirshhorn syndrome, a genetic condition associated
with kidney hypoplasia.
Taken together, these finding suggest that ‘‘embryonic’’ regu-
lators common to Wilms tumor and ESCs maintain a stem-like
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Figure 5. Protein Expression Patterns of
Bivalent Genes in Wilms Tumor and Kidney
Tissue
Genomic views depict K4me3 and K27me3 signals
for (A)KCNJ3 and (B)NR4A2 that are bivalent in the
tumor cells (top panels). Variable transition to a
more active chromatin state is evident in normal
kidney, which is heterogeneous. Immunofluores-
cence images show expression of the correspond-
ing proteins in Wilms tumor and normal kidney
(bottom panels). The images reveal weak expres-
sion in tumor, consistent with the chromatin
patterns, but strong staining of specific epithelial
compartments of normal kidney (red signals).
Nuclei are stained with DAPI (blue signal). Original
magnification 4003. See also Figure S4.
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Wilms Tumor Chromatin Profileschromatin environment conducive to proliferation and essential
for developmental plasticity and specification.
Patterns of Bivalent Chromatin Suggest
a Developmental Arrest in Wilms Tumor
Bivalent domains, which are simultaneously enriched for both
K4me3 and K27me3, correlate to genes that are silent but poised
within a given cell population (Azuara et al., 2006; Bernstein et al.,
2006). In contrast, K27me3-specific domains correspond to
genes that are more stably silenced. As a result, genome-wide
analysis of K27me3 and K4me3 has been useful in defining the
developmental potential of stem cells, including ESCs, neuralCell Stem Cell 6, 591–stem cells, and hematopoietic progeni-
tors (Cui et al., 2009; Mikkelsen et al.,
2007; Pan et al., 2007; Zhao et al., 2007).
We defined a set of 470 ‘‘bivalent’’
genes whose promoters are enriched for
both K27me3 and K4me3 in Wilms tumor
(Set 3; Figure 1C; Table S4). Set 3 genes
exhibit low levels of expression in Wilms
tumor; unlike genes in Set 1 and Set 2,
their transcripts lack K36me3 (Figure S2).
Nearly all Set 3 genes are also bivalent
in ESCs, but few are bivalent in normal
kidney. Because bivalent domains tend
to resolve progressively during differenti-
ation, this suggests that Wilms tumor cells
correspond to a developmental stage
along the normal kidney differentiation
pathway. This conclusion is also consis-
tent with the observation that Set 1 and
Set 2 genes are highly expressed in both
Wilms and fetal kidney, whereas Set 3
genes are more frequently expressed in
adult kidney (Figure 3B; Yusenko et al.,
2009).
Remarkably, when compared to a re-
cently published gene expression atlas
for developing mouse kidney (Brunskill
et al., 2008), a subset of Set 3 genes
shows robust expression in specific
epithelial structures (Figure S4). Of the207 genes with the most structure-specific expression in the
kidney, 18 map to promoters that are bivalent in Wilms tumor.
In contrast, just 3 map to K27me3-specific promoters (see
below). We selected specific examples of bivalent genes for
protein level analysis via immunofluorescence. Although the
blastemal Wilms tumor cells exhibited little or no protein signal
for these genes, expression could be readily identified in specific
epithelial structures of normal kidneys (Figure 5).
To gain insight into developmental pathways that are more
stably inactivated, we collated 188 genes whose promoters
lack K4me3 but are enriched for K27me3 in Wilms tumor (Set 4;
Figure 1C; Table S5). As expected, these genes are largely602, June 4, 2010 ª2010 Elsevier Inc. 597
CDKN2A 5 kb
10 kb
IGF2
IGF2AS
INS-IGF2
INS
5 kb
PEG3PEG3
K4me3
K27me3
K4me3
K27me3
Normal KidneyFetal KidneyWilms Tumor
IGF2
IGF2AS
INS-IGF2
INSIGF2
IGF2AS
INS-IGF2
INS
PEG3
Wilms Tumor
A
C
B
p16 U
p16 M
La
dd
er
U
 D
N
A
M
 D
N
A
W
ilm
s 
1
W
ilm
s 
2
W
ilm
s 
3
K4me3
K27me3
Figure 6. Epigenetic Regulation in Wilms Tumor
(A) Genomic view depicts K4me3 and K27me3 signals for the p16 tumor suppressor locus (CDKN2A). This locus remains intact in the tumor but is silenced by
expansive K27me3 in a pattern reminiscent of normal stem cells.
(B) Methylation-specific PCR (MSP) shows that the p16 locus remains unmethylated at the DNA level, a pattern typical of normal stem cells but distinct from many
adult cancers. Bisulfite-converted DNA was amplified with primers specific for unmethylated (p16 U) or methylated (p16 M) versions of the locus. Gels show PCR
products for unmethylated (U) and methylated (M) genomic DNA controls and three Wilms tumor samples.
(C) Genomic views depict K4me3 and K27me3 signals for imprinted gene loci. IGF2, which has been causally implicated in Wilms tumor, is associated with
a uniquely broad K4me3 domain in Wilms tumor. PEG3 also shows substantially more K4me3 in the tumor.
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(Figure S2).
Set 4 is enriched for genes involved in distinct nonkidney
developmental processes, including brain, limb, ear, and blood
vessel formation (Figure 1C). Nearly all Set 4 genes are biva-
lent in ESCs, but they appear to have become stably inacti-
vated in Wilms. Indeed, the genes show little expression in
both fetal and adult kidneys. Thus, Wilms tumor cells exhibit
a degree of lineage commitment that is distinct from ESCs,
but consistent with a stalled kidney-specific differentiation
program.
Wilms Tumors Maintain Native Epigenetic Silencing
of the p16 Locus
One of the best-studied targets of Polycomb silencing and
K27me3 is the tumor suppressor p16 (Figure 6A). Polycomb
repressors silence p16 during normal development, playing
a particularly key role in proliferating stem cells (Bracken et al.,
2007; Jacobs et al., 1999). The p16 locus frequently undergoes
homozygous deletion or inactivation by DNA methylation in
malignant cells (Herman and Baylin, 2003). p53 inactivation
has been documented in anaplastic Wilms tumors (Bardeesy
et al., 1994), a small subset with poor prognosis, but the mech-598 Cell Stem Cell 6, 591–602, June 4, 2010 ª2010 Elsevier Inc.anism by which most Wilms tumors evade p16-mediated
apoptosis remains undefined.
We used comparative genomic hybridization to evaluate the
p16 locus in the tumors studied here—in all cases we found
both alleles intact. Additionally, methylation-specific PCR con-
firmed that the locus remains unmethylated at the DNA level in
the tumors (Figure 6B). However, the Wilms tumor chromatin
maps reveal a K27me3 domain spanning the p16 locus in a
pattern similar to ESCs and other primary cells (Figure 6A; Cui
et al., 2009; Ku et al., 2008). We speculate that embryonic Poly-
comb proteins and other chromatin regulators expressed in
Wilms tumors underlie a native chromatin environment that
maintains p16 silencing, thereby facilitating tumor proliferation
and antisenescence pathways. It will be important to ascertain
whether Wilms progression is associated with loss of function
of these chromatin regulators, and whether this could account
for increased reliance of anaplastic tumors on deletion or DNA
methylation of p16 and p53 inactivation (Bardeesy et al., 1994;
Natrajan et al., 2008).
Chromatin Patterns of Imprinted Genes in Wilms Tumor
One of the largest K4me3 domains in the Wilms genome coin-
cides with the IGF2 promoter, with no analogous domain present
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imprinting has been implicated as a causal event in Wilms tumor-
igenesis (Ogawa et al., 1993; Weksberg et al., 1993), it is likely
that the active domain reflects this epigenetic event. We there-
fore tested whether alterations in other imprinted genes could
be detected in our data. We found several other imprinted genes,
including NNAT, PEG3, and ZIM2, that showed enrichment of
K4me3 relative to normal kidney (Figure 6C). In the case of
PEG3 and ZIM2, similar signals are seen in fetal kidney, and
thus the marks do not appear tumor specific. Interestingly,
NNAT has been previously shown to be expressed at high levels
in Wilms tumors (Dekel et al., 2006; Li et al., 2002). These data
suggest that imprinting defects in this disease can be detected
at the level of chromatin but appear confined to a limited set
of loci.Aberrant Chromatin Patterns in Early Kidney
Differentiation Genes
Our data suggest that Wilms tumor reflects a stalled kidney-
specific differentiation program. To narrow down the develop-
mental stage of the tumor cells, we examined the chromatin
states of the earliest known markers of kidney differentiation.
The differentiation program of the metanephric mesenchyme
proceeds along separate stromal and epithelial lineages (Mug-
ford et al., 2008). The stromal lineage is characterized and
regulated by FOXD1. Key genes in the earliest epithelial differen-
tiation stages include PAX8, FGF8, WNT4, and LHX1, which are
induced after b-catenin activation (Park et al., 2007). Genetically,
PAX8 and FGF8 appear to act upstream ofWNT4, whereas LHX1
is downstream of this gene (Kobayashi et al., 2005).
Both FOXD1 and LHX1 are bivalent (Set 3) in Wilms tumor,
suggesting that the bulk of blastemal cells are arrested at a stage
preceding the specification of stromal or epithelial lineages. The
bivalent state suggests that these genes remain poised, and this
may relate to the partial differentiation capacity of blastemal
cells, which is evident histologically. FGF8 did not meet the strin-
gent criteria for inclusion in Set 3, but exhibits a moderate degree
of bivalency. In contrast, chromatin at the PAX8 locus is active
whereas WNT4 exhibits neither active nor inactive chromatin
marks.
In summary, although a limited amount of epithelial commit-
ment may be detected at the chromatin level, Wilms cells appear
to maintain the full capacity of the undifferentiated metanephric
mesenchyme, and thus may represent an earlier developmental
stage than previously appreciated through transcriptional
studies.DISCUSSION
Although the genetic basis of Wilms tumor has yet to be fully
characterized, the fact that these tumors are genomically stable
and occur at a young age suggests that relatively few mutations
are involved. The narrow developmental window in which the
tumors arise is thought to reflect the presence of immature
kidney tissue and, in particular, of a renal stem cell population
subject to transformation. These factors suggest that aberrant
retention of stem cell-like transcriptional programs and chro-
matin regulation may play a critical role in this pediatric cancer.In fact, our analyses highlight a set of loci with active chromatin
profiles in Wilms tumor that form an easily recognizable network
reflecting transcriptional programs in early kidney development.
Examples includeSIX2, GDNF, and EYA1, all of which are essen-
tial for the survival of the organ-specific stem cell population
(Brodbeck and Englert, 2004). Other genes, such as SOX11,
exhibit similar chromatin and expression patterns, suggesting
that they may function during kidney development and perhaps
play oncogenic roles in Wilms tumor.
Our results also provide evidence of a specialized chromatin
network in Wilms tumor that is reminiscent of ESCs. The factors
and pathways are largely distinct from those defined in adult
cancers (Table S9; Ben-Porath et al., 2008; Wong et al., 2008).
Some of the implicated chromatin regulators, including NSD1
and WHSC1, have already been linked to Wilms tumorigenesis
and kidney development (Bergemann et al., 2005; Kurotaki
et al., 2002; Nimura et al., 2009; Wang et al., 2007). Although
these genes may play roles akin to oncogenes in adult cancer,
we speculate that their role in Wilms tumor, and possibly other
pediatric cancers, is to maintain an embryonic chromatin
environment conducive to self-renewal and developmental
plasticity.
Further evidence of an arrested developmental program
emerges from an analysis of K27me3 patterns. Our data suggest
that, as in ESCs, bivalent domains in Wilms tumor associate with
genes that may be induced upon differentiation. In fact, the
repertoire of bivalent genes in the tumor includes both early
and late kidney differentiation genes. This suggests that the blas-
temal tumor cells maintain a latent differentiation potential that is
akin to normal renal progenitors, but aberrantly kept in check. In
contrast, developmental genes associated with other lineages
are more frequently enriched for K27me3 alone, and therefore
appear more stably inactivated.
Although our study focused on WTX mutants, which represent
the largest subset of genetically defined Wilms tumors, there is
some evidence that these findings also apply to other genotypes
(Fukuzawa et al., 2009; Li et al., 2004). First, the gene sets
defined here based on chromatin patterns in WTX tumors have
relatively consistent expression patterns across multiple Wilms
tumors that were not selected by genotype (Figures 2D, 2G,
and 3). Second, when we subsequently analyzed K4me3
patterns in a WT1 mutant tumor, we found them to be highly
concordant with the WTX mutant tumors (Figure S1).
In summary, our data suggest that Wilms tumor cells diverge
from a normal developmental course, maintaining self-renewal
capacity and an arrested differentiation program through the
activities of select chromatin regulators and a transcriptional
regulatory network akin to renal progenitors. Although Wilms
tumors could conceivably arise from reprogramming of mature
renal tissue, the narrow developmental window in which these
tumors arise and the maintenance of an array of pathways active
in renal progenitors suggest a close association with a normal
stem cell population. We speculate that kidney stem cells
present early in development represent the cell of origin for
Wilms tumors, and that the transcriptional regulatory network
and chromatin environment of these cells makes them uniquely
susceptible to transformation through the acquisition of minimal
further genetic and epigenetic alterations. Similar mechanisms
may play roles in other pediatric tumors, where transformationCell Stem Cell 6, 591–602, June 4, 2010 ª2010 Elsevier Inc. 599
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with a small number of genetic changes. By contrast, cellular
reprogramming may play a more substantial role in adult tumors,
which are associated with numerous mutations including alter-
ations in chromatin-modifying enzymes (Dalgliesh et al., 2010).
EXPERIMENTAL PROCEDURES
Tumor and Tissue Samples
Surgical samples of primary Wilms tumors, normal kidney, and fetal kidney
were obtained from Boston Children’s Hospital with institutional review board
approval. DNA was prepared with the Puregene DNA Purification Kit (Gentra,
Minneapolis, MN) and RNA was prepared with Trizol (Invitrogen, Carlsbad, CA)
or the RNeasy Mini Kit (QIAGEN, Valencia, CA). Tumor tissues were genotyped
forWTX,WT1, and b-cateninmutations. DNA methylation at the p16 locus was
measured by methylation-specific PCR after bisulfite conversion with the EZ
DNA Methylation Kit (Zymo Research) via PCR primers described previously
(Herman et al., 1996).
Chromatin Immunoprecipitation and High-Throughput Sequencing
ChIP assays for tumor and kidney tissues were performed with a variation of
previously described procedures (Kirmizis et al., 2003; Mikkelsen et al., 2007).
Frozen tissues corresponding to blastemal compartments were thawed, chop-
ped into small fragments, crosslinked in 1% formaldehyde, washed, and
disaggregated into single cells with 50 mm medicones on the Medimachine
(Becton Dickinson). Cells were lysed and sonicated with a Branson 250 to a
size range of 200 to 700 bp. Chromatin was immunoprecipitated with antibody
against K4me3 (Abcam 8580), K27me3 (Upstate 07-449), or K36me3 (Abcam
9050).
Libraries were prepared from5 nanograms of ChIP DNA, loaded onto flow
cells, and sequenced on the Illumina Genome Analyzer by standard proce-
dures (Mikkelsen et al., 2007). Reads were aligned to the reference (hg18)
human genome via Maq (http://maq.sourceforge.net/maq-man.shtml). Statis-
tics on read numbers and alignment are detailed in Table S1.
Chromatin Maps and Initial Data Analysis
Enrichment profiles were generated for each histone modification-cell type
combination as described (Mikkelsen et al., 2007). In brief, aligned reads
were extended to 300 bases to approximate the average ChIP fragment.
Signal was then estimated at any given position (25 bp resolution) as the
number of sequenced ChIP fragments that overlap that position.
A sliding window approach was used to identify significantly enriched inter-
vals or ‘‘peaks’’ from each data set. Thresholds were defined based on a back-
ground model of randomly positioned reads. Peaks of histone modification
were defined by sliding a 700 bp window across the genome and identifying
windows with a minimum average height of 4 reads. We confirmed that these
thresholds yielded few significant peaks when applied to data for control input
samples. Broad K4me3 domains were identified by repeating this procedure
with a 1400 bp sliding window and the same average threshold. In both cases,
enriched intervals separated by less than 100 bp were merged into a single
interval.
Genes from the hg18 RefSeq database were classified based on the
presence of K4me3 and/or K27me3 peaks in their promoter regions (defined
as ±2.5 kb of the transcriptional start sites). Genic K36me3 signals were calcu-
lated based on the average signal across the length of the annotated
transcript. In addition, we collated a set of domains that are farther than
10 kb from the start site of any annotated gene that could correspond to non-
coding RNA transcripts or other elements.
We clustered cell types by K4me3 promoter patterns with the hierarchical
clustering package in GenePattern package (Reich et al., 2006). Clustering
was performed for all three WTX tumors, one WT1 tumor, ESCs, and normal
kidney across all genes via Pearson correlations.
Gene Set Definition
To define Set 1, we identified in each WTX tumor the 3500 most enriched,
broad K4me3 intervals, as defined above. We then retained domains that
appear in all three tumors but do not correspond to a K4me3 peak in normal600 Cell Stem Cell 6, 591–602, June 4, 2010 ª2010 Elsevier Inc.kidney. The nearest promoter to each domain, up to a distance of 2.5 kb,
was included in Set 1. Set 2 includes genes with K4me3 promoter peaks
in the three tumors and in ESCs, but without K27me3 in Wilms or ESCs, or
corresponding K4me3 peaks in normal kidney. Set 3 includes genes with
overlapping K4me3 and K27me3 peaks in at least two out of the three WTX
tumors. Set 4 contains genes with K27me3 promoter peaks but without
K4me3 in all three tumors. Genes that appeared in more than one set were
included in the earlier set (e.g., if a gene met criteria for Set 1 and Set 2, it
was counted only in Set 1). A list of genes with annotated functions in chro-
matin or epigenetic regulation was compiled from genes in Set 1 and Set
2 and also includes a small number of additional genes with active chromatin
in Wilms and ESCs, as in Set 2, but allowing for minimal K4me3 signal in normal
kidney.Expression Analysis
Gene expression data sets for renal tumors, normal kidney, and developing
kidney structures were downloaded from the Gene Expression Omnibus
(Brunskill et al., 2008; Yusenko et al., 2009). Data were normalized with
GCRMA, quantile normalization, and background correction with the Gene-
Pattern package (Reich et al., 2006). For heat maps, only probe sets with at
least one present (‘‘P’’) call across samples and a minimum 1.5-fold difference
between averages of the sample groups were selected. Hierarchical clustering
by Pearson correlation and heat map visualizations used GenePattern. Human
genes were mapped to mouse orthologs as described (Ku et al., 2008).Immunofluorescence
Immunofluorescence was performed for Wilms tumors and fetal kidneys via
standard protocols and the following antibodies: SIX2 (Proteintech), SOX11
(Sigma Prestige HPA000536), KCNJ3/GIRK1 (Abcam ab61191), and NR4A2
(Sigma Prestige HPA000543). Frozen sections were fixed with 4% formalde-
hyde for 15 min and permeabilized with 0.1% Triton-X for 10 min. Incubation
with primary antibodies was performed overnight at 4C. This was followed
by incubation with Alexa Fluor conjugated secondary antibodies for 1 hr at
room temperature (1:2000 concentration).ACCESSION NUMBERS
Chromatin data sets available at Gene Expression Omnibus (GEO) under
accession number GSE20512.SUPPLEMENTAL INFORMATION
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